摘要
目的探讨卵巢上皮性癌(简称卵巢癌)p53和cerbB2表达的临床意义。方法用免疫组织化学法检测p53和cerbB2,结合临床病理及肿瘤的生物学行为进行分析。结果p53在高分化卵巢癌中的表达频率显著低于中、低分化癌,p53表达阳性组的卵巢癌对化疗不敏感,其预后亦明显劣于阴性组卵巢癌。卵巢癌的cerbB2表达与临床期别、组织学类型和分级、残余瘤大小、化疗疗效和预后均无显著相关性。结论p53是评价卵巢癌化疗耐药性和预后的可靠指标。
ObjectiveTo explore the clinical significance of p 53 and c erbB 2 expression in ovarian epithelial carcinoma.MethodsThe expression of p 53 and c erbB 2 were examined by immunohistochemical method,and the relationship between the expression of two factors and clinicopathologic features resistant to chemotherapy and prognosis were analyzed.ResultsThe expression p 53 had significant lower frequency in well differentiated ovarian tumor than that in medium and poor differentiated one.p 53 positive tumors related with drug resistance and poor prognosis significantly.The expression of c erbB 2 was not associated with clinical stage,histologic type,grade, residual tumor,chemotherapy and prognosis.Conclusionp 53 expression in ovarian cancer is related to drug resistance,and it is a useful prognostic index.
出处
《河北医科大学学报》
CAS
2000年第2期87-89,共3页
Journal of Hebei Medical University
关键词
卵巢肿瘤
P53蛋白质
上皮性癌
代谢
药物疗法
ovarian neoplasms/metab
protein p 53 /metab
oncogene/immunol
histological technics
ovarian neoplasms/drug ther
drug tolerance